These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 28681984)

  • 1. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
    Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
    J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
    Liu M; Yao B; Gui T; Guo C; Wu X; Li J; Ma L; Deng Y; Xu P; Wang Y; Yang D; Li Q; Zeng X; Li X; Hu R; Ge J; Yu Z; Chen Y; Chen B; Ju J; Zhao Q
    Theranostics; 2020; 10(10):4437-4452. PubMed ID: 32292506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer.
    Wu X; Liu D; Tao D; Xiang W; Xiao X; Wang M; Wang L; Luo G; Li Y; Zeng F; Jiang G
    Mol Cancer Ther; 2016 May; 15(5):1029-42. PubMed ID: 26939702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
    Liu X; Wu H; Huang P; Zhang F
    J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer.
    Song IS; Ha GH; Kim JM; Jeong SY; Lee HC; Kim YS; Kim YJ; Kwon TK; Kim NS
    Int J Cancer; 2011 Nov; 129(9):2124-33. PubMed ID: 21170990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXO6 promotes gastric cancer cell tumorigenicity via upregulation of C-myc.
    Qinyu L; Long C; Zhen-dong D; Min-min S; Wei-ze W; Wei-ping Y; Cheng-hong P
    FEBS Lett; 2013 Jul; 587(14):2105-11. PubMed ID: 23714368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 Promotes Gastric Cancer Progression and Metastasis through Acetylation-Dependent Stabilization of Snail.
    Qin ZY; Wang T; Su S; Shen LT; Zhu GX; Liu Q; Zhang L; Liu KW; Zhang Y; Zhou ZH; Zhang XN; Wen LZ; Yao YL; Sun WJ; Guo Y; Liu KJ; Liu L; Wang XW; Wei YL; Wang J; Xiao HL; Liu P; Bian XW; Chen DF; Wang B
    Cancer Res; 2019 Oct; 79(19):4869-4881. PubMed ID: 31311807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC protein stability is negatively regulated by BRD4.
    Devaiah BN; Mu J; Akman B; Uppal S; Weissman JD; Cheng D; Baranello L; Nie Z; Levens D; Singer DS
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13457-13467. PubMed ID: 32482868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
    Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
    Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
    Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
    Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
    Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.